Biohaven
Open
$9.56
Prev. Close
$9.55
High
$9.62
Low
$9.56
Market Snapshot
$973.87M
-1.3
-9.36
274
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 274 full-time employees. The company went IPO on 2022-09-23. The company is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
emptyResult
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 274 full-time employees. The company went IPO on 2022-09-23. The company is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Recently from Cashu
Biohaven Advances Troriluzole for Spinocerebellar Ataxia with FDA Priority Review
Biohaven Pharmaceuticals Advances Treatment for Spinocerebellar Ataxia with FDA Priority Review Biohaven Pharmaceuticals announces a significant milestone in its development pipeline as the U.S. Food…
Biohaven's Troriluzole Shows Promise for Spinocerebellar Ataxia Treatment; FDA Review Pending
Biohaven Advances Troriluzole for Spinocerebellar Ataxia Treatment Biohaven Ltd. (NYSE: BHVN) makes significant progress in the treatment of Spinocerebellar Ataxia (SCA), a rare neurodegenerative dise…
Biohaven's Troriluzole: A Game-Changer for Spinocerebellar Ataxia Treatment
Biohaven's Troriluzole: A Potential Breakthrough for Spinocerebellar Ataxia Patients Biohaven Ltd. makes strides in the treatment of Spinocerebellar Ataxia (SCA) with the promising investigational dru…
Biohaven's Strategic Vision: Innovating Therapeutics for Unmet Medical Needs
Biohaven's Focus on Innovative Therapeutics: A Comprehensive Approach to Drug Development Biohaven Ltd. is poised to present its strategic vision at the upcoming 43rd Annual J.P. Morgan Healthcare Con…